Treatment of Warthin's tumor: schlerotherapy and its natural course

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518794-33-00

Enrollment

100

Registered

2024-11-05

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Warthin's tumor

Brief summary

Volume change and symptom chaneg 6 and 12 months after treatment intervention

Interventions

DRUGBleomycin Baxter 15 000 KY injektio-/infuusiokuiva-aine

DRUGliuosta varten

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Volume change and symptom chaneg 6 and 12 months after treatment intervention	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026